RxDoctor Payments Data

Ahmet Dogan, MD

Clinical Pathology/Laboratory Medicine · New York, NYNPI 1457408056

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (47.6%), travel and lodging and speaking fees — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by F. Hoffmann-la Roche AG at 26.0% of the total. Among clinical pathology/laboratory medicine clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$24,545in general payments, 2019–2025

Across 29 payments — averaging $846.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • F. Hoffmann-la Roche AG$6K
  • EUSA Pharma (US) LLC$6K
  • AstraZeneca$5K
  • Seagen Inc.$4K
  • Eli Lilly$2K
  • Incyte Corporation$1K
$1,058,750in research payments, 2019–2025

Across 5 payments — averaging $211,750 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Genentech, Inc.$881K
  • AstraZeneca$177K

What the payments were for

  • Consulting fees$11,69348%
  • Speaking & faculty fees$4,20017%
  • Travel & lodging$7,45930%
  • Food & beverage$1,1935%

General payments by program year

19
20
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
F. Hoffmann-la Roche AG8$6,389
EUSA Pharma (US) LLC6$6,270
AstraZeneca6$4,862
Seagen Inc.7$4,050
Eli Lilly1$1,800
Incyte Corporation1$1,173

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$24,545 in reported general payments places this provider in the 90th percentile of 37 clinical pathology/laboratory medicine providers in New York.

See all clinical pathology/laboratory medicine providers in New York

Medicare billing

Part B allowed, 2024
$80,732
Medicare patients
285
Services billed
1,693

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other clinical pathology/laboratory medicine in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →